Allogene Therapeutics Inc. (ALLO)
NASDAQ: ALLOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALLO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $217.48M
- EPS (TTM)
- -$0.61
- Dividend yield
- None
- 52-week range
- 0.6192 – 4.46
- Day range
- 0.6192 – 0.67
- Volume / Avg
- 7.57M / 7.69M
- Beta
- —
- Shares outstanding
- 346.47M
52-week range
ALLO stock today
Allogene Therapeutics (ALLO) closed at $0.6277 on Nov 20, down 5.88% (-$0.0392), versus the S&P 500's 3.70% decline. At this level, ALLO sits near the bottom of its 52-week range of $0.6192 to $4.46: 85.9% below the high, set on Apr 13, 2026 and 1.4% above the low. ALLO is down 54.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.0%.
Allogene Therapeutics has posted a net loss over the last twelve months (EPS of -$0.61), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Allogene Therapeutics
Company profileAllogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Zachary J. Roberts M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 150
- IPO year
- 2018
- Website
- allogene.com
Financial highlights
Full financialsIn fiscal 2025, Allogene Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Allogene Therapeutics reported a net loss of $190.9 million, compared with a loss of $257.6 million a year earlier. Diluted earnings per share came in at -$0.87.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $22.00K | $95.00K | $156.00K | $114.09M |
| Growth | -100.00% | -76.84% | -39.10% | -99.86% | — |
| Net income | $-190.89M | $-257.59M | $-327.26M | $-340.41M | $-182.05M |
| EPS (diluted) | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$9.00+1333.81%
- Strong buy 3
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.19 vs $-0.13
- Surprise
- -46.15%
ALLO news
All ALLO news- Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient AccessGlobeNewswire
- Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune DiseaseGlobeNewswire
- Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdateGlobeNewswire
- Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual MeetingGlobeNewswire
- Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical DataGlobeNewswire
- Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswire
Allogene Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IPSCCentury Therapeutics Inc. | 1.17 | -11.74% | $211.56M | vs ALLO |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs ALLO |
| CABACabaletta Bio Inc. | 0.9361 | -7.32% | $201.94M | vs ALLO |
| LCTXLineage Cell Therapeutics Inc. | 0.7719 | -5.87% | $195.26M | vs ALLO |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs ALLO |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs ALLO |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs ALLO |
| ARTVArtiva Biotherapeutics Inc. | 3.78 | -1.31% | $186.85M | vs ALLO |
Indexes, lists and sector
Allogene Therapeutics stock FAQ
What is Allogene Therapeutics's stock price today?
ALLO last traded at $0.6277 as of Nov 20, 4:00 PM EST, down 5.88% on the day. Prices are delayed at least 15 minutes.
Who is Allogene Therapeutics's CEO?
Dr. Zachary J. Roberts M.D., Ph.D. is the chief executive officer of Allogene Therapeutics Inc., which has about 150 employees.
What is the ALLO 52-week high?
The 52-week high for ALLO is $4.46 and the 52-week low is $0.6192. The stock is currently 85.9% below its high.